OppenheimerFunds’s TherapeuticsMD TXMD Stock Holding History

OppenheimerFunds’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$10.6M	Buy	43,387 +941	+2%	+$249K	0.01%	660
2018 Q4	$8.09M	Buy	42,446 +1,768	+4%	+$431K	0.01%	684
2018 Q3	$13.3M	Buy	40,678 +2,029	+5%	+$622K	0.02%	673
2018 Q2	$12.1M	Buy	38,649 +5,723	+17%	+$1.75M	0.01%	685
2018 Q1	$8.02M	Buy	32,926 +244	+0.7%	+$68.4K	0.01%	723
2017 Q4	$9.87M	Buy	32,682 +3,179	+11%	+$885K	0.01%	737
2017 Q3	$7.8M	Sell	29,503 -1,181	-4%	-$341K	0.01%	772
2017 Q2	$8.09M	Buy	30,684 +1,478	+5%	+$370K	0.01%	777
2017 Q1	$10.5M	Buy	29,206 +678	+2%	+$210K	0.01%	755
2016 Q4	$8.23M	Buy	28,528 +11,213	+65%	+$3.47M	0.01%	781
2016 Q3	$5.9M	Buy	17,315 +6,024	+53%	+$2.2M	0.01%	807
2016 Q2	$4.8M	Buy	11,291 +158	+1%	+$65.1K	0.01%	807
2016 Q1	$3.56M	Buy	+11,133	New	+$3.8M	﹤0.01%	836

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

OppenheimerFunds's TXMD Position: Q1 2019 in Review

OppenheimerFunds increased its TherapeuticsMD (TXMD) stake by 2.2% in Q1 2019, buying an estimated $249K and bringing the position to 43,387 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #660.

OppenheimerFunds first reported a position in TXMD in Q1 2016 and has held it in 13 quarters since. The position peaked at $13.3M in Q3 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

OppenheimerFunds held 43,387 shares of TherapeuticsMD worth $10.6M as of Q1 2019.
OppenheimerFunds bought 941 TherapeuticsMD shares in Q1 2019, an estimated $249K.
TherapeuticsMD made up 0.01% of OppenheimerFunds's portfolio in Q1 2019, its #660 holding.
OppenheimerFunds first reported a position in TherapeuticsMD in Q1 2016 and has held it in 13 quarters since.
OppenheimerFunds's TherapeuticsMD position peaked at $13.3M in Q3 2018.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.